Homologous recombination Inquiry Through Ovarian Malignancy Investigations
Not Applicable
- Conditions
- Ovarian cancer (including fallopian tube cancer and primary peritoneal cancer)
- Registration Number
- JPRN-UMIN000026303
- Lead Sponsor
- Japanese Gynecologic Oncology Group (JGOG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- Female
- Target Recruitment
- 711
Inclusion Criteria
Not provided
Exclusion Criteria
1. Patients with active concomitant malignancy* except breast cancer. *Includes synchronous multiple cancer and metachronous multiple cancer with less than 5 years of disease free survival. However, excludes skin basal cell carcinoma, skin squamous cell carcinoma, and any other curable lesions with local therapy such as carcinoma in situ or intramucosal carcinoma. 2. Patients who are diagnosed as any other acute/chronic, physically/mentally severe diseases and judged by the primary physician as inappropriate to enroll this study because of safety reasons or any influence to study outcomes. 3. Any other cases that are inappropriate to enroll this study, judged by study principal investigator.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Frequency of HRD in patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer)
- Secondary Outcome Measures
Name Time Method Association between Progression Free Survival (PFS) / Response Rate and HRD in patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer) Association between Progression Free Survival (PFS) / Response Rate and germline mutation in BRCA1/2 gene in patients with ovarian cancer (including fallopian tube cancer and primary peritoneal cancer)